Engineered immune cell therapy for autoimmune diseases
Part of Immune system & allergy clinical trials.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have an autoimmune disease that is moderately to severely active and has not reached complete remission after standard treatment.
- You have been on a steroid combined with another immunosuppressant for at least 2 weeks before starting.
- Your major organs are working well enough (heart, kidney, and liver tests within limits).
- You are not pregnant, planning pregnancy within 6 months, or breastfeeding.
- You have no current severe infections, other active cancers, or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.
This trial tests whether CAR-T cells, a type of immune cell therapy, can help people with certain autoimmune diseases. If you have lupus, scleroderma, or other listed conditions, you may be able to join and see if this treatment can calm your overactive immune system.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.